RADX Key Statistics, Chart & Performance
The current stock price of RADX is 4.28 USD. In the past month the price decreased by -8.59%. In the past year, price decreased by -23.98%.
RADX Latest News, Press Relases and Analysis
RADX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.7 | 395.86B | ||
| AMGN | AMGEN INC | 14.51 | 170.90B | ||
| GILD | GILEAD SCIENCES INC | 15.04 | 152.86B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.69 | 113.14B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.59 | 78.49B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 809.08 | 54.51B | ||
| INSM | INSMED INC | N/A | 41.64B | ||
| NTRA | NATERA INC | N/A | 31.89B | ||
| BIIB | BIOGEN INC | 10.3 | 25.31B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.51 | 21.04B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.24B | ||
| INCY | INCYTE CORP | 14.97 | 18.87B |
Related stock screener links
About RADX
Company Profile
Radiopharm Theranostics Ltd. operates as a pre-clinical and clinical research company. The company is headquartered in Melbourne, Victoria and currently employs 14 full-time employees. The company went IPO on 2021-11-25. The firm has a pipeline of highly differentiated platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer. The clinical program includes one Phase II and three Phase I trials in a variety of solid tumor cancers including lung, breast, and brain. Its technologies include Nano-mAbs, Pivalate, AVB6 Integrin, PSA-mAb, and PTPu. Nano-mAbs is a novel radiopharmaceutical platform made using genetic engineered camelid derived single domain antibodies (sdAb) labelled with a radioisotope of therapeutic radiation. Pivalate is an 18F-FPIA radiotracer, based on a short chain carbohydrate which utilizes the early steps of fatty acid oxidation.
Company Info
RADIOPHARM THERANOSTICS LTD
Level 3, 62 Lygon Street, 62 Lygon Street, Carlton
Melbourne VICTORIA AU
Employees: 14
Phone: 61398245254
RADIOPHARM THERANOSTICS LTD / RADX FAQ
Can you describe the business of RADIOPHARM THERANOSTICS LTD?
Radiopharm Theranostics Ltd. operates as a pre-clinical and clinical research company. The company is headquartered in Melbourne, Victoria and currently employs 14 full-time employees. The company went IPO on 2021-11-25. The firm has a pipeline of highly differentiated platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer. The clinical program includes one Phase II and three Phase I trials in a variety of solid tumor cancers including lung, breast, and brain. Its technologies include Nano-mAbs, Pivalate, AVB6 Integrin, PSA-mAb, and PTPu. Nano-mAbs is a novel radiopharmaceutical platform made using genetic engineered camelid derived single domain antibodies (sdAb) labelled with a radioisotope of therapeutic radiation. Pivalate is an 18F-FPIA radiotracer, based on a short chain carbohydrate which utilizes the early steps of fatty acid oxidation.
Can you provide the latest stock price for RADIOPHARM THERANOSTICS LTD?
The current stock price of RADX is 4.28 USD.
What is the dividend status of RADIOPHARM THERANOSTICS LTD?
RADX does not pay a dividend.
What is the ChartMill technical and fundamental rating of RADX stock?
RADX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the PE ratio for RADX stock?
RADIOPHARM THERANOSTICS LTD (RADX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.72).
Would investing in RADIOPHARM THERANOSTICS LTD be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on RADX.
Can you provide the number of employees for RADIOPHARM THERANOSTICS LTD?
RADIOPHARM THERANOSTICS LTD (RADX) currently has 14 employees.
RADX Technical Analysis
RADX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to RADX. While RADX seems to be doing ok healthwise, there are quite some concerns on its profitability.
RADX Financial Highlights
Over the last trailing twelve months RADX reported a non-GAAP Earnings per Share(EPS) of -3.72. The EPS increased by 85.8% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -44.34% | ||
| ROE | -85.6% | ||
| Debt/Equity | 0 |
RADX Forecast & Estimates
7 analysts have analysed RADX and the average price target is 4.79 USD. This implies a price increase of 11.82% is expected in the next year compared to the current price of 4.28.
For the next year, analysts expect an EPS growth of -12.82% and a revenue growth -100% for RADX